carbostyril has been researched along with Heart Failure in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (52.78) | 18.2507 |
| 2000's | 7 (19.44) | 29.6817 |
| 2010's | 10 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentivenga, C; Berardi, E; Borghi, C; Bui, V; Cicero, AF; Cosentino, ER; Esposti, DD; Landolfo, M; Miceli, R; Spinardi, L | 1 |
| Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T | 1 |
| Berk, E; Christ, T; Engel, A; Galindo-Tovar, A; Gillette, KT; Kaumann, AJ; Molenaar, P; Ravens, U | 1 |
| Belacel-Ouari, M; Domergue-Dupont, V; Fischmeister, R; Hubert, F; Joubert, F; Leblais, V; Manoury, B; Mateo, P; Zhai, K | 1 |
| Calzetta, L; Capuano, A; Donniacuo, M; Gritti, G; Martuscelli, E; Matera, MG; Orlandi, A; Rafaniello, C; Rinaldi, B; Rossi, F; Sodano, L | 1 |
| Akahoshi, Y; Fujiki, H; Ikeda, T; Iwanaga, Y; Miyazaki, S; Morooka, H; Watanabe, H | 1 |
| Au, DH; Carson, SS; Feemster, LC; Krishnan, JA; Lindenauer, PK; Shieh, MS; Stefan, MS | 1 |
| Aronsen, JM; Hougen, K; Levy, FO; Moltzau, LR; Nguyen, CH; Osnes, JB; Qvigstad, E; Sjaastad, I; Skomedal, T | 1 |
| Bae, S; Choi, JH; Choudhury, S; Kang, PM; Ke, Q; Koh, YY; Siu, PM | 1 |
| Afzal, F; Aronsen, JM; Hussain, RI; Krobert, KA; Levy, FO; Osnes, JB; Sjaastad, I; Skomedal, T | 1 |
| Young, JB | 2 |
| Bramer, SL; Kitani, M; Miyamoto, G; Tammara, B; Trang, JM | 1 |
| Ferguson, JW; Hayes, PC; Newby, DE; Therapondos, G | 1 |
| Kelly, C; Sawmiller, DR; Tarpey, SB; Thompson, WJ; Townsley, MI | 1 |
| Bertolet, BD | 1 |
| Britton, LW; Ferraris, VA; Kiser, LM; Sim, MF; Wallace, AM; Weishaar, RE | 1 |
| Arakawa, K; Ichihara, A; Matsumoto, A; Murakami, M; Naitoh, M; Nakamoto, H; Oka, K; Saruta, T; Suzuki, H; Yamamura, Y | 1 |
| Bhat, G; Burwig, S; Eppert, D; Hoit, BD; Walsh, RA | 1 |
| Feldman, AM; Strobeck, JE | 1 |
| Miura, Y; Nakano, H; Nakayama, M; Suzuki, S; Tsuchida, H; Yamada, K; Yoshida, S | 1 |
| Bristow, MR; Eki, Y; Focaccio, A; Krall, J; Movsesian, M; Peeters, G; Roden, R | 1 |
| Ishihara, H; Kanda, H; Kato, R; Nagata, K; Sobue, T; Yokota, M | 1 |
| Kawano, Y; Matsuoka, H; Nishikimi, T; Saito, Y | 1 |
| Bartels, GL; Krauss, XH; Kruijssen, HA; Remme, WJ; Storm, CJ; van der Ent, M; van Hoogenhuyze, DC; van Schelven, D | 1 |
| Fujiki, H; Itoh, S; Mori, T; Tominaga, M | 1 |
| Hartmann, C; McIntire, WS | 1 |
| Abraham, WT; Bristow, MR; Ferguson, DA; Lindenfeld, J; Lowes, BD; Scheffel, CA; White, M; Wolfel, EE | 1 |
| Bartels, GL; Kruijssen, DA; Look, MP; Remme, WJ | 1 |
| Cowart, TD; Feldman, MD; Haber, HL; MacGowan, GA; Tedesco, C; Wu, C | 1 |
| Belenkie, I; Semeniuk, LM; Tyberg, JV | 1 |
| Akamatsu, T; Hirata, T; Horinokuchi, N; Kuro, M; Uchida, O | 1 |
| MacGowan, GA | 1 |
| Steffen, RP; Wastila, WB | 1 |
| Hayashida, W; Kawai, C; Kumada, T | 1 |
| Hague, NL; Hunneyball, IM; Loh, E; Morgan, JP; Perreault, CL; Sim, MF | 1 |
6 review(s) available for carbostyril and Heart Failure
| Article | Year |
|---|---|
New therapeutic choices in the management of acute congestive heart failure.
Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Quinolones; Simendan; Treatment Outcome; Vasodilator Agents | 2001 |
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Diuretics; Heart Failure; Homeostasis; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Animal; Morpholines; Piperidines; Pyrroles; Quinolones; Rats; Spiro Compounds; Vasopressins | 2003 |
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Topics: Animals; Clinical Trials as Topic; Death, Sudden; Heart Failure; Humans; Monitoring, Physiologic; Multicenter Studies as Topic; Neutropenia; Pyrazines; Quinolines; Quinolones | 2004 |
Quinolinone derivatives in the management of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones | 1994 |
Clinical overview of the novel inotropic agent toborinone.
Topics: Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Quinolones | 2000 |
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Phosphodiesterase Inhibitors; Piperidines; Propanolamines; Pyrazines; Quinolines; Quinolones; Vasodilator Agents; Xamoterol | 1992 |
5 trial(s) available for carbostyril and Heart Failure
| Article | Year |
|---|---|
The pharmacokinetics of toborinone in subjects with congestive heart failure and concomitant renal impairment and/or concomitant hepatic impairment.
Topics: Adult; Aged; Cardiotonic Agents; Chromatography, High Pressure Liquid; Female; Heart Failure; Humans; Indicators and Reagents; Infusions, Intravenous; Kidney Diseases; Kidney Function Tests; Liver Diseases; Liver Function Tests; Male; Middle Aged; Quinolones; Reproducibility of Results; Time Factors | 2002 |
Effects of a novel inotropic agent (OPC-18790) on systolic and diastolic function in patients with severe heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Diastole; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pulmonary Wedge Pressure; Quinolones; Radionuclide Ventriculography; Stroke Volume; Systole; Ventricular Function, Left | 1994 |
A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure.
Topics: Cardiotonic Agents; Dobutamine; Heart; Heart Failure; Hemodynamics; Humans; Middle Aged; Oxygen Consumption; Prospective Studies; Quinolones; Vascular Resistance; Vasodilator Agents; Ventricular Function, Left | 1996 |
Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cross-Over Studies; Diuretics; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Pulmonary Wedge Pressure; Quinolones; Single-Blind Method; Vascular Resistance; Ventricular Dysfunction, Left | 1996 |
Study on the effectiveness of toborinone (OPC-18790) in the treatment of heart failure in patients following cardiac surgery.
Topics: Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Extracorporeal Circulation; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Postoperative Complications; Quinolones | 1999 |
25 other study(ies) available for carbostyril and Heart Failure
| Article | Year |
|---|---|
Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Comorbidity; Drug Combinations; Female; Glycopyrrolate; Heart Failure; Heart Ventricles; Humans; Indans; Italy; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Readmission; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines | 2014 |
Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Epinephrine; Female; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Norepinephrine; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Propanolamines; Quinolones; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Rolipram | 2014 |
Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.
Topics: Adrenergic beta-Agonists; Animals; Aorta, Thoracic; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dinoprost; Endothelium, Vascular; Gene Expression; Heart Failure; In Vitro Techniques; Isoproterenol; Male; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Quinolones; Rats, Wistar; RNA, Messenger; Vasoconstriction | 2014 |
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Failure; Heart Rate; Indans; Male; Metoprolol; Myocardial Infarction; Quinolones; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Ventricular Remodeling | 2015 |
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Kidney; Kidney Diseases; Male; Piperidines; Quinolones; Rats, Inbred Dahl; Receptors, Vasopressin; Time Factors; Tolvaptan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Use of Antibiotics Among Patients Hospitalized for Exacerbations of Asthma.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Asthma; Black or African American; Cephalosporins; Comorbidity; Disease Progression; Female; Heart Failure; Hospitalization; Hospitals, Teaching; Humans; Inappropriate Prescribing; Macrolides; Male; Middle Aged; New England; Odds Ratio; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quinolones; Retrospective Studies; Southeastern United States; Tetracyclines; United States; White People | 2016 |
Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition.
Topics: Animals; Apoptosis; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Heart Failure; Male; Myocardial Contraction; Myocytes, Cardiac; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Quinolones; Rats; Rats, Wistar; Receptors, Adrenergic, beta-1; Signal Transduction | 2010 |
Delayed activation of caspase-independent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmA.
Topics: 1-Naphthylamine; Animals; Apoptosis; Apoptosis Inducing Factor; Caspase Inhibitors; Caspases; Disease Models, Animal; Doxorubicin; Heart Failure; Male; Mice; Mice, Transgenic; Mitochondria, Heart; Naphthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Quinolones; Serpins; Viral Proteins | 2010 |
The functional activity of inhibitory G protein (G(i)) is not increased in failing heart ventricle.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Carbachol; Cardiotonic Agents; GTP-Binding Protein alpha Subunits, Gi-Go; Heart Failure; Heart Ventricles; In Vitro Techniques; Isoproterenol; Male; Muscarinic Agonists; Myocardial Contraction; Myocardial Infarction; Pertussis Toxin; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Quinolones; Rats; Rats, Wistar; Rolipram; Ventricular Pressure | 2013 |
Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Capillaries; Capillary Permeability; Colforsin; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Heart Failure; Hydrolysis; Lung; Pacemaker, Artificial; Phosphodiesterase Inhibitors; Pulmonary Circulation; Quinolones; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
Topics: Clinical Trials as Topic; Drug Therapy; Forecasting; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones; Socioeconomic Factors; Time Factors | 2004 |
Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure.
Topics: Captopril; Diltiazem; Heart Failure; Humans; In Vitro Techniques; Milrinone; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Ouabain; Pyridones; Quinolines; Quinolones; Vasodilator Agents | 1994 |
Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Capillary Resistance; Cardiac Output; Cardiac Pacing, Artificial; Diuresis; Dogs; Heart Failure; Hemodynamics; Kidney; Male; Natriuresis; Osmolar Concentration; Piperidines; Potassium; Quinolones; Renin; Sodium | 1994 |
The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Pressure; Diabetes Mellitus, Type 2; Female; Heart Failure; Heart Rate; Humans; Kidney Failure, Chronic; Piperidines; Quinolones | 1993 |
Mechanism of action of OPC-8490 in human ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Action Potentials; Adult; Azetidines; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Enoximone; Heart; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Ion Channels; Middle Aged; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Piperazines; Pyridones; Quinolones; Sotalol; Ventricular Function; Veratridine | 1996 |
Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Administration Schedule; Heart Failure; Hemodynamics; Male; Organ Size; Piperidines; Quinolones; Random Allocation; Rats; Rats, Wistar | 1996 |
Effects of toborinone on myocardial oxygen consumption in pacing-induced heart failure dogs.
Topics: Animals; Cardiac Pacing, Artificial; Cardiotonic Agents; Dogs; Female; Heart; Heart Failure; Hemodynamics; Male; Myocardial Contraction; Myocardium; Oxygen Consumption; Quinolones; Ventricular Function, Left | 1996 |
Amine-oxidizing quinoproteins.
Topics: Amino Acid Sequence; Coenzymes; Copper; Diabetes Mellitus; Dihydroxyphenylalanine; Electron Spin Resonance Spectroscopy; Enzyme Inhibitors; Heart Failure; Humans; Indolequinones; Liver Cirrhosis; Lysine; Menkes Kinky Hair Syndrome; Metalloproteins; Mixed Function Oxygenases; Models, Molecular; Molecular Sequence Data; Oxidation-Reduction; Oxidoreductases Acting on CH-NH Group Donors; PQQ Cofactor; Protein-Lysine 6-Oxidase; Quinolones; Quinones; Semicarbazides; Sequence Homology, Amino Acid; Spectrum Analysis, Raman; Stereoisomerism; Substrate Specificity; Tryptophan | 1997 |
Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Dobutamine; Female; Heart; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Quinolones; Ventricular Function, Left | 1994 |
Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
Topics: Aged; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Neurotransmitter Agents; Quinolines; Quinolones; Vasodilator Agents | 1995 |
Direct myocardial effects of OPC-18790 in human heart failure: beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis.
Topics: Aged; Cardiac Catheterization; Cardiotonic Agents; Diastole; Heart; Heart Failure; Heart Rate; Hemodynamics; Humans; Infusions, Intravenous; Middle Aged; Myocardial Contraction; Quinolones; Systole; Treatment Outcome; Ventricular Function | 1998 |
Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dogs; Enalaprilat; Female; Heart Failure; Hemodynamics; Hydralazine; Male; Nitroglycerin; Phosphodiesterase Inhibitors; Quinolones; Vascular Capacitance; Vasodilator Agents | 1998 |
Cardiovascular pharmacology of the vasodilator-cardiotonic agent, 349U85.
Topics: Animals; Cardiotonic Agents; Cardiovascular System; Cricetinae; Dogs; Heart Failure; Heart Rate; In Vitro Techniques; Male; Milrinone; Myocardial Contraction; Piperidines; Pyridones; Quinolones; Regional Blood Flow; Vasodilator Agents | 1992 |
Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.
Topics: Animals; Calcium; Colforsin; Dose-Response Relationship, Drug; Ferrets; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Male; Milrinone; Myocardial Contraction; Pyridones; Quinolines; Quinolones; Stimulation, Chemical; Vasodilator Agents | 1992 |